Ritter Pharmaceuticals Inc (RTTR) Rating Reiterated by Maxim Group
Ritter Pharmaceuticals Inc (NASDAQ:RTTR)‘s stock had its “buy” rating reiterated by research analysts at Maxim Group in a research note issued to investors on Monday.
The analysts wrote, “Ritter shares have been weak as bloggers have been commenting on the outcome probabilities of the current P2b/3 study. We recently noted that the company has met with the FDA to discuss the statistical analysis plan (SAP) for the upcoming readout of the (N=377) study of RP-G28 in lactose intolerance One possible outcome of the meeting would be to determine if the study could be used as a single registration study” (one) plus one additional pivotal trial.””
A number of other equities research analysts also recently issued reports on RTTR. Aegis restated a “buy” rating on shares of Ritter Pharmaceuticals in a research report on Tuesday, March 7th. Chardan Capital set a $5.00 price objective on Ritter Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, February 19th. Rodman & Renshaw began coverage on Ritter Pharmaceuticals in a research report on Wednesday, January 4th. They set a “buy” rating and a $7.00 price objective on the stock. Roth Capital began coverage on Ritter Pharmaceuticals in a research report on Monday, December 12th. They set a “buy” rating and a $6.00 price objective on the stock. Finally, Zacks Investment Research upgraded Ritter Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, December 13th. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $5.67.
Ritter Pharmaceuticals (NASDAQ:RTTR) traded down 17.70% during midday trading on Monday, hitting $1.86. The company had a trading volume of 586,646 shares. Ritter Pharmaceuticals has a 52 week low of $1.03 and a 52 week high of $3.75. The stock has a 50 day moving average price of $3.08 and a 200 day moving average price of $2.49. The company’s market capitalization is $21.61 million.
Ritter Pharmaceuticals (NASDAQ:RTTR) last announced its quarterly earnings results on Monday, February 27th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.40. Equities analysts forecast that Ritter Pharmaceuticals will post ($1.27) earnings per share for the current fiscal year.
Your IP Address:
In other Ritter Pharmaceuticals news, CEO Michael D. Step purchased 10,000 shares of Ritter Pharmaceuticals stock in a transaction dated Monday, February 27th. The shares were purchased at an average cost of $2.65 per share, for a total transaction of $26,500.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 49.00% of the company’s stock.
Large investors have recently modified their holdings of the company. Alyeska Investment Group L.P. acquired a new stake in shares of Ritter Pharmaceuticals during the fourth quarter valued at $1,768,000. Knoll Capital Management LP acquired a new stake in shares of Ritter Pharmaceuticals during the third quarter valued at $869,000. Finally, Baker BROS. Advisors LP acquired a new stake in shares of Ritter Pharmaceuticals during the third quarter valued at $672,000. Hedge funds and other institutional investors own 9.60% of the company’s stock.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Ratings for Ritter Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.